Proton-pump inhibitor use and hip fractures in men: A population-based case-control study

Annals of Epidemiology

Volumn 24, Issue 4, 2014, Pages 286-290

  Adams, Annette L ^a   Black, Mary Helen ^a   Zhang, Jian L ^a   Shi, Jiaxiao M ^a   Jacobsen, Steven J ^a  

^a Department of Research and Evaluation Kaiser Permanente Southern California ^*  (United States)

Author keywords

Epidemiology; Hip fractures; Pharmacoepidemiology; PPI; Proton pump inhibitor

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; ELECTRONIC MEDICAL RECORD; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; VERY ELDERLY;

EPIDEMIOLOGY; HIP FRACTURES; PHARMACOEPIDEMIOLOGY; PPI; PROTON PUMP INHIBITOR;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; CALIFORNIA; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OMEPRAZOLE; OSTEOPOROSIS; PROTON PUMP INHIBITORS;

EID: 84895503731     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.01.004     Document Type: Article

References (29)

1. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2010. 2011. Available from:. http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/IMSHealthInstitute/Reports/Use_of_Meds_in_the_U.S._Review_of_2010.pdf.
2. O'Connell M.B., Madden D.M., Murray A.M., Heaney R.P., Kerzner L.J. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118(7):778-781. Epub 2005/07/02.
3. Yang Y.X. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 2008, 3(3):204-209. Epub 2008/08/12.
4. Bone health and osteoporosis: A report of the Surgeon General 2004, U.S. Department of Health and Human Services, U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD.
5. Gray S.L., LaCroix A.Z., Larson J., Robbins J., Cauley J.A., Manson J.E., et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010, 170(9):765-771. Epub 2010/05/12.
6. Kaye J.A., Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008, 28(8):951-959. Epub 2008/07/29.
7. Yu E.W., Blackwell T., Ensrud K.E., Hillier T.A., Lane N.E., Orwoll E., et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcified tissue international 2008, 83(4):251-259. Epub 2008/09/25.
8. Chiu H.F., Huang Y.W., Chang C.C., Yang C.Y. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010, 19(11):1131-1136. Epub 2010/09/28.
9. Corley D.A., Kubo A., Zhao W., Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010, 139(1):93-101. Epub 2010/04/01.
10. de Vries F., Cooper A.L., Cockle S.M., van Staa T.P., Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009, 20(12):1989-1998. Epub 2009/04/01.
11. Khalili H., Huang E.S., Jacobson B.C., Camargo C.A., Feskanich D., Chan A.T. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012, 344:e372. Epub 2012/02/02.
12. Pouwels S., Lalmohamed A., Souverein P., Cooper C., Veldt B.J., Leufkens H.G., et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011, 22(3):903-910. Epub 2010/06/30.
13. Targownik L.E., Lix L.M., Metge C.J., Prior H.J., Leung S., Leslie W.D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008, 179(4):319-326. Epub 2008/08/13.
14. Vestergaard P., Rejnmark L., Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcified tissue international 2006, 79(2):76-83. Epub 2006/08/24.
15. Yang Y.X., Lewis J.D., Epstein S., Metz D.C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296(24):2947-2953. Epub 2006/12/28.
16. Eom C.S., Park S.M., Myung S.K., Yun J.M., Ahn J.S. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011, 9(3):257-267. Epub 2011/05/11.
17. Kwok C.S., Yeong J.K., Loke Y.K. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011, 48(4):768-776. Epub 2010/12/28.
18. Lau Y.T., Ahmed N.N. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 2012, 32(1):67-79. Epub 2012/03/07.
19. Ngamruengphong S., Leontiadis G.I., Radhi S., Dentino A., Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011, 106(7):1209-1218. quiz 19. Epub 2011/04/13.
20. Ye X., Liu H., Wu C., Qin Y., Zang J., Gao Q., et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2011, 23(9):794-800. Epub 2011/06/28.
21. Yu E.W., Bauer S.R., Bain P.A., Bauer D.C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011, 124(6):519-526. Epub 2011/05/25.
22. Jacobsen S.J., Cheetham T.C., Haque R., Shi J.M., Loo R.K. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA 2008, 300(14):1660-1664. Epub 2008/10/09.
23. Bergstralh E.J., Kosanke J.L., Jacobsen S.J. Software for optimal matching in observational studies. Epidemiology 1996, 7(3):331-332. Epub 1996/05/01.
24. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15(8):565-574. discussion 75-7. Epub 2006/03/04.
25. Steiner J.F., Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. JClin Epidemiol 1997, 50(1):105-116. Epub 1997/01/01.
26. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JClin Epidemiol 1992, 45(6):613-619.
27. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40(5):373-383.
28. Koepsell T.D., Weiss N.S. Epidemiologic methods: studying the occurrence of illness 2003, Oxford University Press, New York, NY.
29. Geus W.P., Mathot R.A., Mulder P.G., Lamers C.B. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2000, 14(8):1057-1064. Epub 2000/08/10.